Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

26 Mar 2022

Abstract excerpt

The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation-response, mutation-non-response, or mutation-relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with...

Topics

Join the communities discussing this publication.

Acute Myeloid Leukemia Research
Myeloproliferative Neoplasms: Diagnosis and Treatment
Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35406464
DOI: 10.3390/cancers14071689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsPMID 35406464Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

Updates on targeted therapies for acute myeloid leukaemia.Semantic proximity Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

The new era of AML therapy: current standards and emerging targets.Semantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

The clinical impact of the molecular landscape of acute myeloid leukemiaSemantic proximity Read ↗

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.Semantic proximity Read ↗

Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.